UNDER CONSTRUCTION

logo of appeal project
Starting in January 2024, the EU funded project APPEAL with the Coordinator Prof. Rainer König of the Jena University Hospital, Germany, will identify broad spectrum host-directed antiviral drugs (HDA) as promising therapeutic options.
The project aims to (1) establish a computational and experimental pipeline to identify and validate an antiviral for these viruses, and (2) identify at least one broad spectrum antiviral drug against potential emerging and re-emerging viruses as listed by the WHO. To address these, we will implement a drug selection pipeline following several strategies:
We will employ (i) machine learning, based on data from knockout screens, proteomics, protein interaction, transcriptomics of infected cells with pandemic-related viruses, Genome-Wide Association Studies, and generic gene descriptors, (ii) High Density Cell Arrays, which provide much more detailed readouts compared to state of the art pooled knockout screens, (iii) primary cell cultures obtained from a diverse array of human tissues, as they are more appropriate to study the host cell physiology during infection, compared to cancer cell lines, and (iv) use the pipeline to identify host restriction factors, which, when activated, challenge the virus; followed by innovative drug development and delivery based on small activating RNA.
Stacks Image 6
The APPEAL project receives funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101137311.
This publication reflects the views only of the author, and the European Union cannot be held responsible for any use which may be made of the information contained therein.